MKGAF (Merck KGaA) Cyclically Adjusted Revenue per Share: $55.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MKGAF Merck KGaA MKGAF
85 GF Score
Price $155.68
GF Value $159.67
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Cyclically Adjusted Revenue per Share?

Merck KGaA MKGAF -2.65% 85 Cyclically Adjusted Revenue per Share is $55.98 as of Mar. 2026. GuruFocus rates MKGAF with a GF Score™ of 85/100 and a GF Value™ of $159.67 (Fairly Valued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck KGaA's adjusted revenue per share for the three months ended in Mar. 2026 was $13.690. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $55.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck KGaA's average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck KGaA was 10.70% per year. The lowest was 5.40% per year. And the median was 8.40% per year.

As of today (2026-07-27), Merck KGaA's current stock price is $155.677. Merck KGaA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $55.98. Merck KGaA's Cyclically Adjusted PS Ratio of today is 2.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck KGaA was 6.46. The lowest was 2.15. And the median was 3.46.


Merck KGaA  (OTCPK:MKGAF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck KGaA's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=155.677/55.98
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck KGaA was 6.46. The lowest was 2.15. And the median was 3.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck KGaA Cyclically Adjusted Revenue per Share Related Terms


Merck KGaA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Cyclically Adjusted Revenue per Share Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.07 43.78 48.89 50.38 58.27

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.59 56.77 57.50 58.27 55.98

MKGAF vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Cyclically Adjusted PS Ratio falls into.


MKGAF
85GF Score
Merck KGaA MKGAF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck KGaA's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=13.69/131.2583*131.2583
=13.690

Current CPI (Mar. 2026) = 131.2583.

Merck KGaA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 9.866 100.717 12.858
201609 9.603 101.017 12.478
201612 9.307 101.217 12.069
201703 9.475 101.417 12.263
201706 9.551 102.117 12.277
201709 9.634 102.717 12.311
201712 9.933 102.617 12.705
201803 9.832 102.917 12.540
201806 10.013 104.017 12.635
201809 10.036 104.718 12.580
201812 10.235 104.217 12.891
201903 9.630 104.217 12.129
201906 10.320 105.718 12.813
201909 10.283 106.018 12.731
201912 11.118 105.818 13.791
202003 11.119 105.718 13.805
202006 10.669 106.618 13.135
202009 12.037 105.818 14.931
202012 12.837 105.518 15.969
202103 12.694 107.518 15.497
202106 13.495 108.486 16.328
202109 13.454 109.435 16.137
202112 13.563 110.384 16.128
202203 13.141 113.968 15.135
202206 13.538 115.760 15.350
202209 13.204 118.818 14.586
202212 13.813 119.345 15.192
202303 13.028 122.402 13.971
202306 13.212 123.140 14.083
202309 12.700 124.195 13.422
202312 13.086 123.773 13.877
202403 12.830 125.038 13.468
202406 13.251 125.882 13.817
202409 13.438 126.198 13.977
202412 13.073 127.041 13.507
202503 13.125 127.779 13.482
202506 13.941 128.412 14.250
202509 14.324 129.255 14.546
202512 14.175 129.361 14.383
202603 13.690 131.258 13.690

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $55.98 mean?
Merck KGaA (MKGAF) has a Cyclically Adjusted Revenue per Share of $55.98 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Cyclically Adjusted Revenue per Share too high?
Merck KGaA's current Cyclically Adjusted Revenue per Share is $55.98. Overall, Merck KGaA has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Merck KGaA's Cyclically Adjusted Revenue per Share of $55.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck KGaA and its competitors. Merck KGaA's current Cyclically Adjusted Revenue per Share is $55.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (MKGAF) is currently considered Fairly Valued. The stock's GF Value™ is $159.67, compared to a current price of $155.68 — trading 2.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $55.98. Merck KGaA's overall GF Score™ is 85/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck KGaA (MKGAF), the current Cyclically Adjusted Revenue per Share is $55.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (MKGAF) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of $155.68 is trading 2.5% below its estimated GF Value™ of $159.67. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MKGAF:

  • Cyclically Adjusted Revenue per Share: $55.98
  • GF Value™: $159.67 vs. price of $155.68 (2.5% below fair value)
  • GF Score™: 85/100 with 10 warning signs

No single metric tells the full story. See the MKGAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
85GF Score

Get the complete analysis for MKGAF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$155.68
Price
$159.67
GF Value